Minapharm Pharmaceuticals (CAI:MIPH) Long-Term Debt: E£1,503 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAI:MIPH Minapharm Pharmaceuticals CAI:MIPH
41 GF Score
Price E£760.00
GF Value E£363.03
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Minapharm Pharmaceuticals Long-Term Debt?

Minapharm Pharmaceuticals CAI:MIPH +1.04% 41 Long-Term Debt is E£1,503 Mil as of Dec. 2025. GuruFocus rates CAI:MIPH with a GF Score™ of 41/100 and a GF Value™ of E£363.03 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Minapharm Pharmaceuticals's Long-Term Debt for the quarter that ended in Dec. 2025 was E£1,503 Mil.

Minapharm Pharmaceuticals's quarterly Long-Term Debt declined from Jun. 2025 (E£2,405 Mil) to Sep. 2025 (E£2,206 Mil) and declined from Sep. 2025 (E£2,206 Mil) to Dec. 2025 (E£1,503 Mil).

Minapharm Pharmaceuticals's annual Long-Term Debt increased from Dec. 2023 (E£1,335 Mil) to Dec. 2024 (E£2,250 Mil) but then declined from Dec. 2024 (E£2,250 Mil) to Dec. 2025 (E£1,503 Mil).

Minapharm Pharmaceuticals  (CAI:MIPH) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Minapharm Pharmaceuticals Long-Term Debt Related Terms

Minapharm Pharmaceuticals Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Minapharm Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minapharm Pharmaceuticals Long-Term Debt Chart

Minapharm Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
603.87 1,036.29 1,335.48 2,249.76 1,502.95

Minapharm Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,249.76 2,399.81 2,405.44 2,206.50 1,502.95
CAI:MIPH
41GF Score
Minapharm Pharmaceuticals CAI:MIPH
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of E£1,503 Mil mean?
Minapharm Pharmaceuticals (CAI:MIPH) has a Long-Term Debt of E£1,503 Mil as of Dec. 2025.
Is Minapharm Pharmaceuticals' Long-Term Debt too high?
Minapharm Pharmaceuticals' current Long-Term Debt is E£1,503 Mil. Overall, Minapharm Pharmaceuticals has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' Long-Term Debt compare to ZTS and UTHR?
Minapharm Pharmaceuticals' Long-Term Debt of E£1,503 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Minapharm Pharmaceuticals's current Long-Term Debt is E£1,503 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£363.03, compared to a current price of E£760.00 — trading 109.3% above its estimated fair value. The current Long-Term Debt is E£1,503 Mil. Minapharm Pharmaceuticals' overall GF Score™ is 41/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current Long-Term Debt is E£1,503 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?

Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued. The current stock price of E£760.00 is trading 109.3% above its estimated GF Value™ of E£363.03. GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CAI:MIPH:

  • Long-Term Debt: E£1,503 Mil
  • GF Value™: E£363.03 vs. price of E£760.00 (109.3% above fair value)
  • GF Score™: 41/100 with 10 warning signs

No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Minapharm Pharmaceuticals Business Description

Address El-Bardissi Street, 2T Takseem Asmaa Fahmy Street, Heliopolis, Cairo, EGY
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
41GF Score

Get the complete analysis for CAI:MIPH

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£760.00
Price
E£363.03
GF Value